 MacroGenics Inc. MGNX, -3.20 shares were halted late Tuesday after the biotech drug developer said its breast-cancer treatment didnt perform as well as standard treatment in a late-stage clinical study. MacroGenics shares finished the regular session down 3.2 at 21.78. 